• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transfusion therapy for sickle cell disease
The clinical presentations of sickle cell disease include acute pain, acute chest syndrome, stroke and acute anaemia and blood transfusion therapy can be used effectively in the emergency setting for the treatment of many of these complications. Long‐term blood transfusion therapy is also used for the prevention of disease complications with most evidence for its use in primary stroke prevention. Transfusion can be given as a simple or top‐up transfusion or as an exchange transfusion and donor red cells should be haemoglobin S negative and as a minimum matched for ABO, full Rh and Kell type. Repeated transfusions lead ...
Source: ISBT Science Series - January 29, 2016 Category: Hematology Authors: J. Howard, S. E. Robinson Tags: Invited Review Source Type: research

The role of blood transfusion in Sickle Cell Disease
Blood transfusion is used in the treatment and prevention of acute and chronic complications of Sickle Cell Disease. Blood may be administered in the emergency situation as a simple top‐up transfusion or as an automated or manual exchange procedure. Elective transfusions may be offered as an one‐off procedure, often pre‐operatively or as a long‐term regime, usually for primary or secondary stroke prevention. The main complications of transfusion in this patient population are alloimmunization, hyperhaemolytic transfusion reactions and iron overload.
Source: ISBT Science Series - May 31, 2013 Category: Hematology Authors: J. Howard Tags: Supplement Article Source Type: research

Safety and effectiveness of a Patient Blood Management Programme in surgical patients – the study design for a multicentre epidemiological non‐inferiority trial by the German PBM network
ConclusionsThis trial will determine whether the implementation of a PBM programme is safe and effective in terms of clinical outcome. Data will be compared to data prior to implementation of PBM in (the same?) 20 Germany hospitals.
Source: ISBT Science Series - April 13, 2015 Category: Hematology Authors: P. Meybohm, D. P. Fischer, E. Herrmann, C. Geisen, M. M. Müller, E. Seifried, A. U. Steinbicker, C. F. Weber, K. D. Zacharowski, Tags: Invited Review Source Type: research

The new oral anticoagulants: clinical use and reversal agent development
Warfarin has been the centre of oral anticoagulant therapy for over 60 years. Recent development of new oral anticoagulants (NOACs) has provided a safe and effective alternative for stroke prevention in patients with atrial fibrillation and for prevention of venous thromboembolism. Determination of their use in acute coronary syndrome has been hampered by increases in bleeding events in most large trials, especially when used with antiplatelet therapy. NOACs have equal or superior efficacy and safety profiles compared to warfarin, fewer drug interactions; no dietary restrictions; predictable responses that eliminates moni...
Source: ISBT Science Series - April 13, 2015 Category: Hematology Authors: J. Costin, J. Ansell, S. Bakhru, B. Laulicht, S. Steiner Tags: Invited Review Source Type: research

Mesenchymal stem/stromal cell‐derived extracellular vesicles as a new approach in stem cell therapy
Mesenchymal stem or stromal cells (MSCs) are widely applied in regenerative and immune modulating therapies. Initially, it was assumed that administered MSCs integrate into damaged tissues to exert their clinical functions. However, in recent years accumulating evidence has been provided that MSCs rather act in a paracrine than a cellular manner. To this end, extracellular vesicles (EVs), which are secreted by MSCs in vivo and in vitro, seem to exert the MSCs’ therapeutic effects. So far, MSC‐EVs have been shown to improve functional recoveries following ischemic events, such as stroke and myocardial infarction, and to...
Source: ISBT Science Series - January 29, 2016 Category: Hematology Authors: V. Börger, M. Bremer, A. Görgens, B. Giebel Tags: Invited Review Source Type: research

Therapeutic apheresis
Apheresis is a procedure to separate and collect or remove a particular blood component. Apheresis may be used for collecting a therapeutic dose of component, remove the circulating amount of harmful component/substances, or collect a particular blood cell/precursor from a patient for reinfusion. Therapeutic plasma exchange (TPE) is a therapeutic procedure in which the plasma is removed and replaced with a replacement solution. It is used primarily for the removal of pathological immunoglobulin. Red cell exchange is a procedure in which the patient's red cells are removed and replaced with the donor red cells. It is usuall...
Source: ISBT Science Series - June 27, 2016 Category: Hematology Authors: T. Triyono Tags: Invited Review Source Type: research

Developing new pharmacotherapeutic approaches to treating sickle ‐cell disease
Survival for patients with SCD has been prolonged by improvements in supportive care, including vaccinations, antibiotic prophylaxis and overall medical management, including transfusion. However, there remains only one approved, partially effective drug for sickle‐cell disease—hydroxyurea (hydroxycarbamide). The world desperately needs better ways of both treating and preventing the recurrent painful vaso‐occlusive episodes pathognomonic of sickle‐cell disease as well as the end‐organ damage that still leads inexorably to severely shortened life expectancies throughout the world. Based on accumulating knowledge ...
Source: ISBT Science Series - July 31, 2016 Category: Hematology Authors: M. J. Telen Tags: Congress Review Source Type: research